Patent intelligence · US
US 9555090
Equine encephalitis virus vaccines and methods of using thereof
Equine encephalitis virus vaccines and methods of using thereof
Patent details — US 9555090
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 31, 2017
- Expiration
- Jan 26, 2037
- Claims
- 19
- CPC classes
- A61K, A61K2039/525, A61K2039/5252, A61K2039/5254
Quick answer
US 9555090 (Equine encephalitis virus vaccines and methods of using thereof) is held by The United States of America as repesented by the Secretary of Army, on behalf of the U.S. Army Medical Research Institute of Infections Diseases. Status: granted. Granted Jan 31, 2017. Expires Jan 26, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K2039/525, A61K2039/5252, A61K2039/5254, A61K2039/53, A61K2039/70
More from The United States of America as repesented by the Secretary of Army, on behalf of the U.S. Army Medical Research Institute of Infections Diseases
Related pharmaceutical patents in our USPTO index.
-
US 12419873
Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases
granted -
US 12419941
Poultry drinking water-based vaccine delivery system and method
granted -
US 12415845
Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
granted -
US 12410240
Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
granted -
US 12410259
CD47 targeted therapies for the treatment of infectious disease
granted -
US 12404317
T cell receptors recognizing MHC class II-restricted MAGE-A3
granted -
US 12397066
Delivery of gene therapy treatments
granted -
US 12398123
Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria
granted
Frequently asked questions
What is US patent 9555090?
US 9555090 (Equine encephalitis virus vaccines and methods of using thereof) is held by The United States of America as repesented by the Secretary of Army, on behalf of the U.S. Army Medical Research Institute of Infections Diseases. Status: granted. Granted Jan 31, 2017. Expires Jan 26, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9555090?
The United States of America as repesented by the Secretary of Army, on behalf of the U.S. Army Medical Research Institute of Infections Diseases is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3,720 pharmaceutical patents for this assignee.
When does US 9555090 expire?
Our index shows an expiration date of Jan 26, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.